Chardan analyst Daniil Gataulin initiated coverage of Annexon (ANNX) with a Buy rating and $16 price target The firm cites the commercial potential of the company’s complement C1q inhibitors tanruprubart in Guillain-Barre syndrome and vonaprument in geographic atrophy for the Buy rating. It sees additional upside potential from tanruprubart in Huntington’s disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX: